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ABSTRACT 
Objectives: 
The main objective of the present thesis was to explore cognitive impairment in patients with 
Parkinson’s disease (PD), focussing on non-demented patients and elucidating cognitive 
profile, the course and predictive power of cognitive impairment for the development of 
dementia.  
Methods: 
The sample of 139 patients with PD was drawn from an epidemiological study of PD 
performed in Rogaland County, Norway in 1993. In 1997, the survivors performed a baseline 
evaluation consisting of neurological, psychiatric and neuropsychological assessments. They 
were re-assessed 4 years later with the same test-battery. A group of 38 healthy elderly 
controls performed the same neuropsychological test battery at baseline, in order to obtain 
normative data.  
PD was diagnosed according to explicit and generally accepted criteria based on clinical 
examination. The cognitive assessment consisted of a battery of neuropsychological tests 
assessing visual memory (Benton Visual Retention Test, multiple choice version), 
visuospatial abilities (Judgement of Line Orientation), and executive functions (Stroop Word 
Test), as well as of two screening instruments: the Mini Mental Status Examination (MMSE) 
and Dementia Rating Scale (DRS). Dementia in PD was diagnosed according to Diagnostic 
and Statistical Manual of Mental Disorders, 3rd edition, revised (DSM- III-R) criteria based on 
a semi-structured clinical caregiver-based interview and the results of the neuropsychological 
tests. The diagnosis of mild cognitive impairment (MCI) was made according to a modified 
version of the criteria proposed by Petersen et al 2001. 
Results: 
Fifty-five percent of the PD patients without dementia were cognitively impaired. Impairment 
on the Stroop Word Test was associated with an increased risk for incident dementia.  Thirty-
eight PD patients (52.7%) who fulfilled the criteria for MCI were identified. The progression 
rate to dementia after 4 years was 60% in subjects with MCI, compared to only 20% among 
the cognitively intact PD patients. Finally, cognitive heterogeneity was found both in patients 
with MCI and with dementia: In both groups, the majority exhibited a predominantly 
executive impairment (i.e. “subcortical” cognitive profile), although a considerable proportion 
had a predominantly memory impairment (i.e. “cortical” cognitive profile).  
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Conclusions: 
These findings show that cognitive impairment is common even in non-demented patients 
with PD, and that MCI is an early manifestation of the dementia in PD. The cognitive profiles 
indicate that in most patients with PD, fronto-subcortical changes are the main contributing 
factor to dementia, whereas in other patients, cortical and hippocampal changes predominate.  
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INTRODUCTION 
 
Parkinson’s disease 
 Parkinson’s disease (PD) is a common neurodegenerative disorder. The prevalence of 
PD is 100-150 patients per 100000 inhabitants (Mutch, Dingwall-Fordyce, Downie, Paterson, 
& Roy, 1986; Tandberg, Larsen, Nessler, Riise, & Aarli, 1995). It increases with age, 
reaching a maximum around 75-80 years, affecting about 1.5% of people aged 65 or older (de 
Rijk et al., 1997; Tandberg et al., 1995). PD is present in all countries were prevalence studies 
have been conducted, in all ethnic groups, and is approximately equally prevalent in men and 
women (Zhang & Roman, 1993). The specific aetiology of PD remains unknown in most 
cases. However, genetic factors, infections and sub-clinical intoxications, as well as head 
trauma and vascular disease, have all been suggested as possible risk factors (Duvoisin, 1993; 
Rybicki, Johnson, Uman, & Gorell, 1993; Tipton, McCrodden, & Sullivan, 1993). 
The cardinal clinical features are resting tremor, bradykinesia, rigidity and postural 
instability. Pathologically, PD is defined as a loss of dopaminergic neurones in the substantia 
nigra, with the formation of α-synuclein positive Lewy bodies (LB) within the remaining 
neurones (Braak et al., 2002). In addition to degeneration of the dopaminergic system, other 
ascending subcortical neurotransmitter systems are affected as well: the cholinergic system 
(nucleus basalis of Meynert), the noradrenergic system (locus coeruleus), and the serotonergic 
system (dorsal raphe nuclei) (Jellinger, 1999a). Cortical changes, LB and amyloid plaques, 
and neurofibrillary tangles (NFT) are also found in most patients at autopsy (Jellinger, Seppi, 
Wenning, & Poewe, 2002).  
  
Diagnosis of Parkinson’s disease 
  PD is found in approximately 70% of patients with parkinsonism. The diagnosis of PD 
is mainly based on medical history and clinical examination. Criteria for the clinical diagnosis 
of PD have been proposed in the literature (Hughes, Daniel, Kilford, & Lees, 1992; Larsen, 
Dupont, & Tandberg, 1994). Functional imaging, in particular the visualisation of the 
dopamine transporter by means of recently developed tracers with single photon emission 
computed tomography (SPECT), may be useful for effecting a differential diagnosis (Chou et 
al., 2004; Walker et al., 2004). 
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Differential diagnosis of Parkinson’s disease   
 The clinical differentiation of PD from other types of parkinsonism is critically 
important for effective management, evaluation of prognosis, and research. Thus, PD must be 
differentiated from the secondary parkinsonism induced by neuroleptics or other causes (i.e. 
intoxication, infections, traumatic, and vascular) as well as from parkinsonism which arises in 
the course of other neurodegenerative diseases (i.e. Alzheimer’s disease (AD), dementia with 
Lewy bodies (DLB), multiple system atrophy (MSA), and progressive supranuclear palsy 
(PSP)). The following findings are suggestive of PD: 1) resting tremor; 2) no atypical motor 
signs; 3) lack of dementia and obvious autonomic deficiency at the onset of the disease; 4) 
asymmetrical disease, particularly among the elderly; 5) no demonstrable precipitating 
factors; 6) good response to levodopa /apomorphine test. 
 
Clinical heterogeneity within patients with Parkinson’s disease 
  The clinical heterogeneity within the patient population with PD is well recognised  
with different neuropathological mechanisms underlying PD, and genetic factors as well as 
different aetiologies thought to contribute to this heterogeneity (Foltynie, Brayne, & Barker, 
2002; Lewis, Foltynie et al., 2005). Different cohorts of patients have been robustly identified: 
younger onset, tremor dominant, non-tremor dominant, and rapid disease progression. The 
subgroup of PD patients with young onset of disease (Dubois, Pillon, Sternic, Lhermitte, & 
Agid, 1990; Giovannini et al., 1991) is charactherized by a slower rate of disease progression 
(Goetz, Tanner, Stebbins, & Buchman, 1988; Jankovic et al., 1990; Zetusky, Jankovic, & 
Pirozzolo, 1985) and a greater potential to develop motor fluctuations, possibly as a 
consequence of prolonged levodopa exposure (Gibb & Lees, 1988; Hughes, Daniel, Blankson, 
& Lees, 1993) , compared with subgroups of later disease onset. Many studies have pointed 
out the distinction between a benign “tremulous” form of the disease compared with the more 
aggressive  “ bradykinetic-rigid” form. The tremor dominant subgroup have a slower rate of 
disease progression (Jankovic et al., 1990; Zetusky et al., 1985) and less cognitive impairment 
(Mortimer, Pirozzolo, Hansch, & Webster, 1982; Portin & Rinne, 1987; Zetusky et al., 1985). 
By contrast, PD patients in the non-tremor dominant subgroup  are afflicted with mild 
depression and executive impairment. A final subgroup of PD patients includes patients with 
a rapid rate of motoric disease progression, but no marked cognitive impairment. These 
patients may comprise a parkinsonian syndrome other than idiopathic PD in light of their 
more rapid natural history (Colosimo, Albanese, Hughes, de Bruin, & Lees, 1995; Wenning, 
Ben Shlomo, Magalhaes, Daniel, & Quinn, 1994).  
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 Previous studies have suggested differing neural pathologies for distinct motor 
symptoms, such as akinesia (Morrish, Sawle, & Brooks, 1995; Nandi, Aziz, Giladi, Winter, & 
Stein, 2002) and tremor (Doder, Rabiner, Turjanski, Lees, & Brooks, 2003; Parker, Tzourio, 
Blond, Petit, & Mazoyer, 1992) as well as the cognitive features of the disease (Dubois, Pilon, 
Lhermitte, & Agid, 1990; Ito et al., 2002; Lewis, Dove, Robbins, Barker, & Owen, 2003; 
Mattay et al., 2002). It is likely that different clinical subgroups have different pathological 
processes and foci (Brooks, 1999; Jellinger, 1999b), which in turn may have different 
aetiologies.  
 Defining subgroups of patients with PD is helpful in delineating the natural history, 
prognosis and therapeutic options. Thus, identification of different patient subgroups may be a 
helpful predictor for current management strategies and also relevant to neurosurgical 
interventions and pharmacological treatment of cognitive impairment in PD. 
 
Cognitive functioning in Parkinson’s disease 
  
Contrary to the claim of James Parkinson who first described the disease that the 
intellect is preserved (Parkinson, 1817), the clear evidence is that cognitive impairment is 
common even in early PD and affects a variety of cognitive functions (Foltynie, Brayne, 
Robbins, & Barker, 2004; Janvin, Aarsland, Larsen, & Hugdahl, 2003; Levy, Jacobs et al., 
2002; Muslimovic, Post, Speelman, & Schmand, 2005; Weintraub, Moberg, Culbertson, 
Duda, & Stern, 2004). In many instances these impairments may not be clinically apparent, 
but are detectable with specific neuropsychological tests. As the disease progresses, a 
substantial proportion of patients with PD develop dementia (Emre, 2003; Aarsland, 
Andersen, Larsen, Lolk, & Kragh-Sorensen, 2003). In addition, other neuropsychiatric 
symptoms, such as visual hallucinations, depression and apathy, are also common (Aarsland 
& Karlsen, 1999).  Thus, it is increasingly recognised that PD is also a neuropsychiatric 
disorder and not merely a movement disorder. In addition to being common, there is 
convincing evidence demonstrating the clinical importance of such symptoms for the quality 
of life of patients and their caregivers, as well as the health-economic impact due to increased 
risk for nursing home admission (Schrag, Jahanshahi, & Quinn, 2000; Aarsland, Larsen, 
Tandberg, & Laake, 2000).  
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Executive functions 
Impairment of executive functions (defined as the ability to plan, organise, and 
regulate goal-directed behaviour) constitutes the core feature of neuropsychological 
dysfunction in PD patients (Litvan, Mohr, Williams, Gomez, & Chase, 1991; Pillon, Deweer, 
Agid, & Dubois, 1993; Pillon, Dubois, Lhermitte, & Agid, 1986). The term refers to 
impairment in concept formation and rule finding, problem solving, set elaboration and 
planning, set shifting, and set maintenance (Pillon, 2001). These impairments are similar, but 
not identical (Owen, 1993) to those seen in patients with frontal lesions and are thought to 
represent a dysfunction of the fronto-striatal neuronal circuitry (Rogers, 1998; Rowe, 2002).  
 
Visuospatial abilities  
Visuospatial impairment has been described in patients with PD (Montse, 2001; 
Pillon, Dubois, Ploska, & Agid, 1991), even when tests reveal few motor component 
involvement  (Hovestadt, 1987). In non-demented patients with mild to moderate PD visual 
impairment has been found to correlate with impairments in cognition (i.e. executive 
functions and verbal memory), postural control and gait, and functional disability (Uc et al., 
2005). Furthermore, visuospatial impairment was found to be more severe in patients with PD 
and dementia (PDD) than in AD patients with an equivalent severity of dementia (Huber, 
Shuttleworth, & Freidenberg, 1989; Mosimann et al., 2004; Mosimann et al., 2005; Stern, 
Richards, Sano, & Mayeux, 1993).  It has been suggested that such visuospatial impairment 
may be at least partly attributable to frontal-executive dysfunction in addition to deficit in 
temporal and parietal cortices.  
 
Memory  
Memory impairment has frequently been reported in PD and is characterised by poor 
free recall, but relatively better recognition than free recall.  Impaired immediate and delayed 
recall can largely be remedied by semantic cueing or probing (Pillon et al., 1993; Scheltens, 
1999), suggesting that the memory deficits in PD may be due to retrieval problems  (Jacobs et 
al., 1995; Stern, Marder, Tang, & Mayeux, 1993; Aarsland, Andersen et al., 2003), as 
opposed to the deficient encoding seen in AD (Helkala, 1988; Kramer, 1989; Massman, Delis, 
Butters, Levin, & Salmon, 1990). This may reflect a deficiency in internally-cued search 
strategies due to the dysexecutive syndrome (Pillon, 2001). However, a recent study 
demonstrated that although a frontal-type memory impairment was the most common memory 
profile in PD, a considerable subgroup showed impairment of both recall and recognition, a 
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pattern similar to that found in patients with AD (Weintraub et al., 2004). This finding 
suggests that hippocampal pathology, which in fact is common in PD (Junque et al., 2005; 
Tam, Burton, McKeith, Burn, & O'Brien, 2005) may also contribute to memory impairment in 
a subgroup of patients with PD. 
   
Attention 
Attentional dysfunction is prominent among the cognitive impairments described in 
PD and is probably closely related to the executive function impairment reported in these 
patients. This hypothesis is supported by several studies showing that attentional dysfunction 
appears most usually in connection to complex tasks requiring shifting and/or sustained 
attention (Downes et al., 1989; Lewis, Slabosz, Robbins, Barker, & Owen, 2005; Wright, 
Burns, Geffen, & Geffen, 1990), as well as mental calculations that require sustained mental 
tracking (Huber, 1990). Attentional dysfunction is a characteristic feature of dementia in PD 
(PDD) and DLB, and consists both of reduced and fluctuating performance (Ballard et al., 
2002). The underlying pathological substrate of this dysfunction is not yet clear, but metabolic 
activity (O'Brien, Firbank, Mosimann, Burn, & McKeith, 2005) and cholinergic deficits in the 
thalamus (Ziabreva et al., 2005)  have been put forward as being responsible.  
 
Speed of mental processing   
Several studies have shown mental slowing (i.e. bradyphrenia) in PD (Cooper, Sagar, 
Tidswell, & Jordan, 1994; Mayeux, Stern, Sano, Cote, & Williams, 1987), although this is 
still a matter of  considerable controversy in the literature. It has been suggested that the 
finding of reduced cognitive speed may very well have been caused by the inclusion of 
patients with mild dementia or depression (Smith, Goldman, Janer, Baty, & Morris, 1998).  
However, recent studies support the early literature, and suggest that mental slowing, possibly 
secondary to attentional dysfunction, is in fact a symptomatic characteristic of patients with 
LB associated dementia. 
  
Summary and unresolved issues 
In summary, there is convincing evidence that cognitive functioning is affected in 
patients with PD, even early in the course of the disease. However, divergent findings 
concerning the frequency and severity of impairment of the various cognitive domains have 
been reported. These are probably due to the small and selected patient samples which 
characterize most studies, as well as the idiosyncratic features of the disease itself.  Overall, 
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the cognitive pattern is typically characterised by impaired executive functions, including 
attention and visuospatial abilities, in addition to memory impairment, which is usually less 
pronounced.  
There are, however, a number of unresolved issues requiring further investigation. The 
clinical profile and course in PD differ markedly, and clinical subgroups of PD have been 
proposed. However, since nearly all studies have presented findings on overall group means 
rather than how individuals are clustered into subgroups, little is known as to whether 
subgroups of PD patients with different cognitive profiles in fact exist. This is perhaps to be 
expected, given the findings of subgroups with different motor profiles in PD (Lewis, Foltynie 
et al., 2005). Preliminary evidence indicates that there is also cognitive heterogeneity in PD, 
but very few studies have explored this to any meaningful depth, and the possibility of 
cognitive subgroups in PDD has not been explored at all. Another largely unresolved issue is 
cognitive functioning over time, and whether the early and mild cognitive impairments in PD 
are stable or progress to dementia. Comparison between studies is hampered by 
methodological differences, such as the different diagnostic criteria for PD, the selection of 
patients, with most studies being based on convenience samples from highly specialised 
centers and thus not necessarily representative of the population of PD, the criteria to define 
dementia, and the methods used to assess cognition.  
 
Clinical correlates of cognitive dysfunction in Parkinson’s disease 
 
 Age and age of onset 
 Several studies have explored the demographic and clinical factors associated with 
cognitive impairment. Later onset of the disease has been associated with increased risk for 
cognitive dysfunction and subsequent dementia in several studies (Hobson & Meara, 2004; 
Mahieux et al., 1998; Muslimovic et al., 2005). In contrast, other studies found that age at 
entry in the study (Hughes et al., 2000; Levy, Jacobs et al., 2002; Stern, Marder et al., 1993; 
Aarsland et al., 2001), but not age at onset was associated with later onset of dementia. 
Overall, it would seem that PD patients with early disease onset have less severe cognitive 
problems than patients with later disease onset, and have a disease that progresses more 
slowly, although it is not yet clear whether the effect of age at onset is independent of the 
effect of age itself (Marder, 2005). 
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Medication effects 
 Levodopa is widely used for the treatment of motor symptoms, but there is a lack of 
consensus regarding its effect on cognition in PD. Treatment with levodopa has been reported 
to either improve (Cooper et al., 1992; Downes et al., 1989), impair (Gotham, Brown, & 
Marsden, 1988; Kulisevsky et al., 1996) or not affect (Pillon, Dubois, Bonnet et al., 1989) 
frontal cognitive performance in patients with PD (i.e. working memory, set switching), and 
to improve (Cooper et al., 1992; Rogers, Lees, Smith, Trimble, & Stern, 1987), impair 
(Huber, Shulman, Paulson, & Shuttleworth, 1989; Poewe, Berger, Benke, & Schelosky, 1991) 
or not affect (Kulisevsky et al., 1996; Rafal, Posner, Walker, & Friedrich, 1984) memory 
functions. One possible explanation for these discrepant findings is that the effect of levodopa 
depends on whether the brain area responsible for the cognitive domain is depleted of 
dopamine or not. Thus, if cognitive dysfunction is associated with dopaminergic deficit in a 
specific brain area, levodopa treatment may improve functioning. In contrast, if the cognitive 
dysfunction is caused by problems with brain circuits not depleted of dopamine, levodopa 
may in fact lead to dopaminergic overstimulation and worsening of the function (Kulisevsky, 
2000). Although limited research exists, there is some evidence that dopamine agonists may 
also influence cognition in PD, and that the effect may differ according to the 
pharmacological characteristics. Specifically, preliminary evidence suggested that the D2/D3 
agonist pramipexole, but not the D1/D2 agonist pergolide may worsen cognitive functions 
such as verbal fluency, verbal memory and attentional-executive functions (Brusa et al., 2003; 
Brusa et al., 2005). 
Several studies have found that anticholinergic treatment impairs memory and other 
cognitive functions in PD (Dubois et al., 1987; Sadeh, Braham, & Modan, 1982), and has 
even been associated with inducing morphological changes such as accumulation of amyloid 
plaques and NFT (Perry, Kilford, Lees, Burn, & Perry, 2003). However, other studies report 
no evidence of memory deterioration (Levin, Llabre, Reisman, Weiner, & Brown, 1991). 
Glutamatergic overstimulation exists in PD and may contribute to cognitive impairment. 
Accordingly, glutamatergic antagonists, such as amantadine, may therefore protect against 
cognitive decline. Convincing evidence supporting this hypothesis is lacking, however. 
Further studies including studies with drug naïve patients are needed to resolve the impact of 
pharmacological drugs on cognitive functioning in PD, particularly from a longitudinal 
perspective. 
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Motor symptoms and cognitive impairment 
 Studies of the association between cognitive and motor symptoms in patients with PD 
have revealed several consistent trends. First, patients with predominant postural instability 
(Zetusky et al., 1985), gait disorder(Alves, Larsen, Emre, Wentzel-Larsen, & Aarsland, 2006; 
Pillon, Dubois, Cusimano et al., 1989), rigidity (Huber, Paulson, & Shuttleworth, 1988; 
Marttila & Rinne, 1976), and bradykinesia (Ebmeier et al., 1990; Huber et al., 1988; Marttila 
& Rinne, 1976) exhibit greater cognitive impairment than patients with tremor dominant 
disease. Second, more severe motor symptoms have consistently been associated with a more 
rapid cognitive decline and increased risk of dementia (Marder, Tang, Cote, Stern, & Mayeux, 
1995; Stern, Marder et al., 1993; Aarsland et al., 2001; Aarsland et al., 2004). Finally, there is 
some evidence suggesting that the side of the motor onset may influence cognitive outcome, 
with  the left-sided onset group performing poorer than the right on several cognitive 
measures, including immediate and delayed recall, word retrieval, semantic verbal fluency, 
attention, and mental tracking (Tomer, Levin, & Weiner, 1993), although such a relationship 
has not been consistently observed (Finali, Piccirilli, & Rizzuto, 1995; St Clair, Borod, 
Sliwinski, Cote, & Stern, 1998). 
  In summary, patients with tremor dominant disease seem to have less severe cognitive 
impairment than those with predominant postural instability and gait disturbance. 
    
Cognition and depression in Parkinson’s disease 
There is a close and enigmatic relationship between depression and PD. Prevalence 
estimates of depression in PD range from 7% to 90%, depending on the diagnostic criteria and 
selection of the study population (Nilsson, Kessing, Sorensen, Andersen, & Bolwig, 2002; 
Tandberg, Larsen, Aarsland, Laake, & Cummings, 1997; Troster, 2000; Aarsland & 
Cummings, 2002). Depression seems to be more common in PD with dementia (Tandberg, 
Larsen, Aarsland, & Cummings, 1996; Veazey, Aki, Cook, Lai, & Kunik, 2005) . On the 
other hand, depression is considered to be a risk factor for PD (Leentjens, Van den Akker, 
Metsemakers, Lousberg, & Verhey, 2003; Schuurman et al., 2002). As is also the case in 
depressed patients without PD, depression is associated with cognitive impairment, 
particularly in executive and memory tasks (Kuzis, Sabe, Tiberti, Leiguarda, & Starkstein, 
1997; Norman, Troster, Fields, & Brooks, 2002; Starkstein et al., 1989; Troster, Paolo et al., 
1995; Troster, Stalp, Paolo, Fields, & Koller, 1995). These findings are consistent with 
neuroimaging studies showing greater frontal and temporal lobe metabolic abnormalities in 
patients with depression with or without PD (Mayberg, 1994; Mayberg et al., 1990). Recent 
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research suggests that mild depression probably has little if any impact on cognition in PD, 
and that depression must be of at least moderate severity before it has a significant impact on 
cognition (Boller, Marcie, Starkstein, & Traykov, 1998; Starkstein, 1993).  Whether 
depression is associated with a later development of dementia in PD is still a controversial 
issue. One older study (Stern, Marder et al., 1993) indicated that depression was a risk factor 
for dementia in PD, while other studies did not (Hobson & Meara, 2004; Hughes et al., 2000; 
Mahieux et al., 1998; Aarsland et al., 2001). Since depression has consequences for PD 
patients and their caregivers in terms of quality of life (Karlsen, Tandberg, Arsland, & Larsen, 
2000; Aarsland, Larsen, Karlsen, Lim, & Tandberg, 1999), it is important to properly  
diagnose and treat depression in PD. Furthermore, studies of the effects of depression on 
cognition need to control for the possible effect of antidepressants on cognition, since these 
may ameliorate aspects of cognitive dysfunction in these patients (Norman et al., 2002). 
In summary, certain demographic and clinical characteristics are associated with 
cognitive performance in PD. Age, and possibly age at onset, more severe parkinsonism, in 
particular non-tremor symptoms such as rigidity and postural symptoms, to some extent 
antiparkinsonian agents, and depression, have all been found to be negatively associated with 
cognition in PD. 
 
 Mild cognitive impairment in Parkinson’s disease 
 Mild cognitive impairment (MCI) is common in the general population (Graham et 
al., 1997; Waite, Broe, Grayson, & Creasey, 2001) and it refers to a transitional state between 
the cognition of normal ageing and mild dementia (Diagnostic and statistical manual of 
mental disorders, 1994).  Subjects with MCI have been found to have an increased risk of 
dementia, with an annual progression to dementia between 6% and 15% (Petersen et al., 
1999). Recently, different MCI subtypes were described, and a classification into amnestic, 
single domain non-memory, and multiple domains slightly impaired MCI was suggested 
(Petersen et al., 2001). A recent study (Lopez et al., 2006) described the neuropsychological 
characteristics of MCI subgroups, providing further support for the classification of MCI in 
different subtypes. In addition, there is some evidence that the different MCI subtypes 
progress to different types of dementia disorders. Patients with amnestic MCI usually progress 
to Alzheimer’s disease at a high rate (Petersen et al., 1999), while patients with a single non-
memory MCI (i.e. executive or visuospatial impairment) are more likely to progress to a non-
AD dementia such as dementia with Lewy bodies (Boeve, 2004), fronto-temporal dementia, 
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vascular dementia or primary progressive aphasia (Petersen, 2004). Although the concept of 
MCI is largely accepted in the context of AD, it has not been validated for PD populations.  
Different cognitive profiles may exist within PD. In a study of recently diagnosed 
patients with PD, (Foltynie et al., 2004) 11% had a specific fronto-striatal type impairment, 
8%  a specific temporal lobe type impairment, and 18%  impairments in both domains (global 
impairment).  However, few prospective studies of cognition in PD have been reported, and 
thus the rate of progression to dementia from the different cognitive MCI types in PD is as yet 
unknown. Overall, the annual rate of cognitive decline in PD is stable over time, but with 
wide inter-individual variations (Aarsland et al., 2004). Executive and memory impairments 
have been found to be associated with a subsequent development of dementia in PD (Levy, 
Jacobs et al., 2002; Woods & Troster, 2003), but how this finding relates to the progression 
from MCI to dementia in individual patients is unclear.  
 
Cognitive impairment in Parkinson’s disease with dementia  
There is abundant evidence showing that dementia is more common in PD than in the 
general population. The point prevalence of dementia in PD is approximately 31% (Aarsland, 
Zaccai, & Brayne, 2005). Since dementia is associated with increased mortality (de Lau, 
Schipper, Hofman, Koudstaal, & Breteler, 2005; Levy, Tang et al., 2002), prospective studies 
are needed to accurately describe the frequency of dementia in PD.  Patients with PD have an 
almost six-fold risk for becoming demented compared to healthy controls (Aarsland et al., 
2001), and the cumulative prevalence rises steadily. In one study following a PD sample for 8 
years, the cumulative prevalence of dementia approached 80% (Aarsland, Andersen et al., 
2003).  
The dementia associated with PD resembles that observed in subcortical dementia 
(Cummings, 1990). Qualitatively, the neuropsychological profile of patients with PDD 
encompasses the same type of deficits found in non-demented PD patients (Girotti et al., 
1988): marked deficits in executive function, attention, and visuospatial and constructional 
abilities (Dubois & Pillon, 1997). Memory is also impaired, although recall can be improved 
by cueing when compared with AD (Pillon, Dubois, & Agid, 1991; Stern, Richards et al., 
1993).  A similar pattern of cognitive impairment is found in DLB (Aarsland, Litvan et al., 
2003), suggesting that similar neuropathological mechanisms might be involved. The 
cognitive pattern in DLB and PDD has been described as reflecting the superimposition of 
fronto-subcortical cognitive deficits on the cortical deficits typically associated with AD 
(Galasko, 2000). 
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 Previous studies of the cognitive profiles in PD patients have been based on mean 
group data that may mask differences in cognitive patterns in subgroups of patients. To our 
knowledge, no study has yet investigated differences in the cognitive impairment profiles 
within the group of patients with PDD, and thus whether a similar cognitive heterogeneity as 
described in mildly impaired PD patients exists also in PD patients with dementia. 
Knowledge of the pattern of cognitive impairment profiles within the group of patients 
with PDD would be helpful in the clinical diagnosis of patients with dementia and 
parkinsonism, and also provide information about the relative contribution of the different 
neuropathological and neurochemical factors underlying the cognitive dysfunction (for 
example, the contribution of dopaminergic and/or non-dopaminergic mechanisms, and 
cortical or subcortical lesions), with potential importance to effective pharmacotherapy of 
dementia in PD.  
 
Pathophysiology of cognitive dysfunction in Parkinson’s disease 
The variety of cognitive impairments in PD suggests that a number of different 
neurochemical and neuropathological factors contribute to these cognitive changes. Executive 
impairment is related to the dopaminergic deficits, caused by either disruption of the nigro-
striatal circuitry with altered outflow from the caudate nuclei to the frontal cortex via the 
thalamus (Lewis et al., 2003; Rinne et al., 2000) or diminished dopamine activity in the 
frontal projections consequent to degeneration of mesocortical projections (Mattay et al., 
2002). This hypothesis is supported by the worsening of executive functioning, but not 
memory, after withdrawal of levodopa (Lange, Paul, Naumann, & Gsell, 1995). Although the 
exact contribution of non-dopaminergic transmitter changes to the cognitive impairments in 
PD is not known, there is some evidence linking the cortical noradrenergic system to 
extradimensional shift performance (Robbins, 2003), whereas visual memory may be 
dependent on acetylcholine rather than being dopamine dependent (Lange et al., 1992).  
However, cholinergic deficits may also contribute to the executive and attentional deficits 
(Bohnen et al., 2006). 
 The more extensive global cognitive impairment in the later disease stages suggests 
that cortical regions become involved. Brain imaging with SPECT revealed a differential  
relationship between cortical perfusion and cognitive functions, with temporal and parietal 
perfusion exhibiting a relationship to global cognitive impairment, while dorsolateral frontal 
perfusion relates to executive impairment (Firbank, Colloby, Burn, McKeith, & O'Brien, 
2003; Jagust, Reed, Martin, Eberling, & Nelson-Abbott, 1992; Mito et al., 2005). 
 19
Furthermore, with increasing cognitive impairment, cerebral atrophy probably adds to the 
neurochemical changes, and recent studies using MRI have demonstrated widespread areas of 
cortical atrophy in frontal, temporal and parietal cortices (Burton, McKeith, Burn, Williams, 
& JT, 2004; Tam et al., 2005). 
The aetiology of dementia in PD is not yet established in detail. Previous studies have 
reported that Alzheimer-type changes, i.e. neuritic plaques and NFT are the main correlates of 
dementia in PD (Braak et al., 1996; Cordato, Halliday, Harding, Hely, & Morris, 2000; de 
Vos, Jansen, Stam, Ravid, & Swaab, 1995; Jellinger et al., 2002). On the other hand, it has 
recently been suggested that the LB degeneration in PD is not confined to the brain stem, but 
rather develops in stages which subsequently involve the basal forebrain, limbic structures 
and finally neocortical association areas (Braak, Ghebremedhin, Rub, Bratzke, & Del Tredici, 
2004). Recent studies, using more sophisticated staining methods, have indeed suggested that 
the limbic and cortical LB lesions are the main pathological correlate of dementia in PD 
(Apaydin, Ahlskog, Parisi, Boeve, & Dickson, 2002; Braak, Rub, Jansen Steur, Del Tredici, 
& de Vos, 2005; Hurtig et al., 2000; Kovari et al., 2003; Samuel, Galasko, Masliah, & 
Hansen, 1996; Aarsland, Perry, Brown, Larsen, & Ballard, 2005). In addition, hippocampal 
atrophy has commonly been reported in PDD (Junque et al., 2005; Tam et al., 2005). Thus, a 
wide range of neurochemical and morphological changes develop in PD, potentially inducing 
or at least contributing to cognitive impairment and dementia. It is likely that the relative 
importance of these changes varies among the different patients, but this is not yet understood 
in detail. The direct relationship of these diverse pathological changes to the different 
cognitive deficits in patients with PD and PDD is not established. Detailed clinico-pathologic 
and related studies are needed to provide answers to these questions. 
 
Pharmacological treatment of dementia in Parkinson’s disease 
There are currently no treatments available to limit the LB neurodegenerative process 
in PD. However, pharmacological agents can influence several of the neurochemical changes. 
As stated above, clinical experience and clinical trials indicate that treatment with levodopa 
does not have a major functional impact on the dementia of PD. As discussed above, there is 
convincing evidence to suggest that cholinergic deficits (i.e. related to cellular loss in the 
nucleus basalis of Meynert) play a role in the aetiology of cognitive deficits in PD (Dubois, 
Ruberg, Javoy-Agid, Ploska, & Agid, 1983; Perry et al., 1985). These findings have led to 
pharmacological studies of cholinergic agents in PD. Several open-label and small, placebo-
controlled studies with cholinesterase inhibitors have indicated that these agents may be 
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effective (Leroi et al., 2004; Aarsland, Hutchinson, & Larsen, 2003; Aarsland, Laake, Larsen, 
& Janvin, 2002). These preliminary findings were recently confirmed in a large-scale placebo 
controlled trial with rivastigmine, showing that rivastigmine had a positive effect not only on 
cognition, but also on neuropsychiatric symptoms and the activities of daily living. (Emre et 
al., 2004), as well as several aspects of attention (Wesnes, McKeith, Edgar, Emre, & Lane, 
2005).   
 
 
OBJECTIVES OF THE STUDY 
 
1) To examine the frequency and characteristic profile of cognitive impairment in non-
demented patients with PD, and the association with demographic and clinical variables 
2) To examine whether cognitive impairments in PD can predict the development of 
dementia. 
3) To explore the frequency of mild cognitive impairment in patients with PD, whether 
different subtypes of mild cognitive impairment exist, and whether mild cognitive impairment 
is associated with the development of dementia.  
4) To identify the pattern of cognitive profile within sub-groups of patients with PDD. 
 
 
HYPOTHESES OF THE STUDY 
  
1) Non-demented patients with PD will exhibit impairment in several cognitive domains, and 
it is predicted that this impairment is associated with older age, depression, and more severe 
parkinsonism, in particular severity of non-tremor symptoms. 
2) Impairment on selected cognitive tests predicts incidence of dementia in patients with PD. 
3) Subgroups of PD patients with different types of mild cognitive impairment have an 
increased risk of developing dementia compared to patients with intact cognition. 
4) Different impairment profiles are predicted within the group of PDD patients. One sub-
group will exhibit a subcortical-type profile, whereas another sub-group a more cortical 
dementia type. The distribution of cognitive profiles is characteristic for patients with LB type 
dementia and distinct from that in patients with AD. 
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SUBJECTS AND METHODS 
 
Subjects 
The patients were recruited from an epidemiological study of PD in the county of 
Rogaland, Norway conducted between 1992 and 1993.  A total of 245 PD patients were 
identified after a comprehensive selection procedure, yielding a prevalence of PD of 110.9 per 
100.000 inhabitants (Tandberg et al., 1995). During 1996/1997 the survivors were invited to 
participate in the baseline evaluation of the present study and were given a comprehensive 
assessment consisting of neurological, psychiatric and neuropsychological evaluation. Of the 
245 patients evaluated in 1993, 7 had subsequently been diagnosed as not having PD, 88 had 
died, and 11 choose not to participate in the study. Accordingly, 139 patients participated at 
the baseline evaluation and represented the study population. Seventy-six patients were free of 
dementia, 58 were demented, and 5 received a diagnosis of questionable dementia. The 
sample of PD without dementia represented the at-risk population studied in papers 1 to 3. 
These patients were re-assessed 4 years later (2000/2001) with the same evaluations 
(neurological, psychiatric and neuropsychological) performed at baseline. Sixty patients with 
PD performed the follow-up evaluation (13 patients had died, and 3 refused to participate). 
 The control group consisted of 38 healthy elderly subjects who were either relatives 
of the patients or relatives of inpatients in the psychogeriatric ward at the Stavanger 
University Hospital. They performed the same cognitive test battery at baseline as PD patients 
to obtain normative data. The age and gender distribution as well as education were similar to 
the patients with PD. None had a history of alcoholism, drug abuse, psychiatric illness, 
Central Nervous System (CNS) disease, or head injury, and none were currently taking 
centrally active drugs. Individuals with evidence of intellectual deterioration (Mini Mental 
Status Examination score ≤24) (MMSE) (Folstein, Folstein, & McHugh, 1975) were not 
included.   
 Fifty of the 58 patients diagnosed with PD and dementia completed the Dementia 
Rating Scale (DRS) (Mattis, 1976) and represented the population studied in the fourth paper. 
The remaining 8 patients had severe dementia and were not able to perform the DRS. The 
performance on the DRS was compared with the performance of 62 patients with DLB, and 
39 patients with AD. The patients with DLB were recruited from the Alzheimer Research 
Center at the University of California San Diego, US in whom the DRS had been 
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administered during life and who had undergone autopsy post mortem. The patients with AD 
were consecutive patients attending the outpatient clinic of the Section of Geriatric 
Psychiatry, Stavanger University Hospital. 
    
Diagnosis and clinical evaluation of Parkinson’s disease 
Information on disease history, drug therapy, response to levodopa and demographic 
variables was obtained in a semi-structured interview conducted by a neurologist. A diagnosis 
of PD required the presence of at least two of the four cardinal symptoms of PD and at least a 
moderate response to levodopa. Patients with clinically significant cognitive impairment at 
disease onset, other neurological diagnoses or drugs which could cause parkinsonism, or the 
presence of radiological structural brain abnormalities compatible with diagnoses other than 
PD were excluded (Larsen et al., 1994). The clinical examination of the motor symptoms 
consisted of a complete Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn, 1987) 
assessment, including the Hoehn & Yahr scale (Hoehn & Yahr, 1967). The diagnostic 
evaluation was performed at each evaluation, and only those patients who fulfilled the 
diagnostic criteria for PD at each examination were included. Autopsy has been performed in 
a subgroup of 22 patients of this cohort, and in all cases, the neuropathological diagnosis was 
consistent with PD.  Patients with motor fluctuations were assessed in the “ON” phase. 
 
Assessment of cognition 
Patients with PD and a MMSE score >16 and control subjects were given a 
neuropsychological battery assessing cognitive domains known to be affected in PD, 
including visual memory, visuospatial abilities, and executive functions. The selected 
neuropsychological tests were to the fullest extent possible independent of motor abilities. 
The tests were administered by a neuropsychologist, and scored according to conventional 
procedures outlined in the test manuals. The following neuropsychological tests were 
included:   
(i) The multiple choice version of the Benton Visual Retention Test (Benton, 1974) 
designed to assess short-time visual memory: subjects recognise one or more 
designs that they have seen before. The test consists of 15 items, each item being 
presented for 10 seconds.   
(ii) (ii) The Judgement of Line Orientation Test (Benton, Varney, & Hamsher, 1978) 
designed to assess visual/spatial abilities: subjects estimate the angular relationship 
between line segments by visually matching angled line pairs to 11 numbered radii 
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forming a semicircle. The test consists of 30 items, each showing a different pair 
of angled lines to be matched to the display cards. Its two forms, H and V, present 
the same items but in different order. Score corrections are provided for both age 
and sex (Benton, 1994).    
(iii)  (iii) The Stroop Word Test (Golden, 1978) designed to assess selective 
attention/executive functions. Several versions of the Stroop Word Test are 
available on the market and they differ from each other with regard to the number 
of trials required to fulfil the test and the number of items on each card. The 
version used in the present study consists of three cards, each card containing 6x8 
items: subjects name the colours of coloured patches (1st card), read printed words 
(2nd card), and read printed colour names in which the ink used for printing is a 
colour different from the colour designed by the printed name (3rd card). Both the 
time needed to complete each card and the number of errors was recorded.        
 In addition, two brief screening instruments were administered: the DRS (Mattis, 1976) 
and the MMSE (Folstein et al., 1975). The DRS is divided into five subtests (attention, 
conceptualisation, initiation and perseveration, construction, and memory) and provides a 
total score and five subscale scores. The scale has been shown to robustly and accurately 
distinguish the dementia profile of cortical and subcortical dementias (Paulsen et al., 1995; 
Salmon, Kwo-on-Yuen, Heindel, Butters, & Thal, 1989). For individuals with PD, the scale 
has been shown to be a valid mental screening test of cognitive functioning and the subtests 
show strong convergent and discriminant validity (Brown et al., 1999). MMSE assesses 
orientation, learning, short- term memory, concentration, and higher cortical functions and it 
is widely used in order to differentiate between cognitively intact and cognitively impaired 
elderly subjects. Population-based, age- and education- corrected normative data are available 
for both DRS and MMSE (Crum, Anthony, Bassett, & Folstein, 1993; Lucas et al., 1998).  
    
Diagnosis of dementia 
  
Diagnosis of dementia in Parkinson’s disease  
A semi-structured interview based on the Diagnostic and Statistical Manual of Mental 
Disorders, third edition, revised (DSM-III-R) (Diagnostic and statistical manual of mental 
disorders, 1987) criteria for dementia was administered to the caregiver by a psychiatrist with 
experience in geriatric psychiatry and neuropsychiatry. Two experienced clinical researchers, 
a psychiatrist and a neurologist, made the diagnosis of dementia according to the DSM-III-R 
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criteria for dementia as based on the clinical interview, the cognitive screening and the 
neuropsychological tests. To qualify for a diagnosis of dementia, the interview, the rating 
scales and the neuropsychological tests had to be compatible with a diagnosis of dementia. 
Population-based, age-and education-corrected normative data for the MMSE (Crum et al., 
1993) and DRS (Lucas et al., 1998) were used, and scores below the lowest quartile (MMSE) 
or below the 19th percentile (DRS) were considered as cognitive impairment. Impairment on 
the neuropsychological tests was considered to be present if the score was at least 1.5 standard 
deviations below the mean for the control subjects. In cases of inconsistencies among these 
measures, all available material was reviewed, and both raters made a diagnosis of dementia 
or no dementia independently, according to the DSM-III R criteria for dementia. A final 
diagnosis was made by consensus. 
 
Diagnosis of dementia with Lewy bodies                                                                                                              
The diagnosis of DLB was necropsy confirmed in all patients. All patients with DLB were 
diagnosed clinically as having dementia at the time of their initial evaluation. The procedures 
used to prepare and study the brains of the patients with DLB have been described in detail 
before (Hansen & Samuel, 1997). The neuropathological diagnosis of DLB required the 
presence of subcortical and cortical LB. 
 
  Diagnosis of Alzheimer’s disease 
The patients with AD were diagnosed according to ICD-10 (International 
classification of diseases, 1992) criteria for AD. The diagnosis of AD was based on 
interviews with patients and caregivers, cognitive testing, physical examination, routine blood 
tests, and cranial computed tomography or MRI. None of the patients had either parkinsonism 
or clinically significant psychiatric symptoms. 
    
Diagnosis of mild cognitive impairment  
A diagnosis of MCI was made according to a modified version of the criteria proposed by 
Petersen et al (Petersen et al., 2001). MCI was defined as impaired performance (i.e. 1 1/2 
standard deviation or more below the mean of the control group) on one, two or all three 
neuropsychological tests. In addition, information regarding memory complaint or other 
subjective cognitive complaints was gathered by means of the caregiver-based interview and 
the mentation item from the Mental Subscale of UPDRS (Fahn, 1987). To qualify for a 
diagnosis of MCI in this thesis, cognitive impairment should not be severe enough to affect 
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activities of daily living, and thus the criteria for dementia were not met. Based on the 
performance on the cognitive tests, three subtypes of cognitive impairment were described:  
1) Amnestic MCI: individuals with impaired performance on the Benton Visual 
Retention Test, but who are performing reasonably well on the other 
neuropsychological tests. 
2) Multiple domains slightly impaired: impairment on two or more cognitive tests. 
3) Single non-memory domain: impairment in a single cognitive domain other than 
memory, i.e. on Judgement of Line Orientation or Stroop Word Test. 
 
 Psychiatric assessment         
  The patients with PD completed the Beck Depression Inventory (BDI)(Beck, 1978), a 
frequently used depression questionnaire with proven psychometric properties in PD 
(Leentjens, Verhey, Luijckx, & Troost, 2000; Visser, Leentjens, Marinus, Stiggelbout, & van 
Hilten, 2006). A cut-off score of 10 was used in order to differentiate between depressed and 
non-depressed PD patients (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). They also 
completed the Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) which is an 
instrument specifically designed to assess psychopathology in patients with brain disorders. 
The NPI has proved validity and reliability in patients with dementia and assesses both the 
frequency and severity of 10 syndromes: delusions, hallucinations, agitation, depression, 
anxiety, euphoria, apathy, disinhibition, irritability, and abnormal motor output. 
 
 
SUMMARY OF REPORTS 
 
Report 1: Neuropsychological profile of patients with Parkinson’s disease without dementia.  
 In order to describe the frequency of neuropsychological impairment and its profile in 
PD patients without dementia, a sample of 103 PD patients was compared with a control 
group consisting of 38 healthy elderly subjects. Dementia was diagnosed in 27 patients. 
Among the 76 non-demented patients, 34 (45%) had no cognitive impairment and 42 (55%) 
had a mild cognitive impairment. Within the cognitively impaired PD group, three different 
types of cognitive profile were identified: 11 patients (26.1%) exhibited only executive 
dysfunction, 7 patients (16.6%) impaired visual memory and /or visuospatial abilities without 
executive dysfunction, and 19 patients (45.2%) a global cognitive impairment.   
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Report 2: Cognitive predictors of dementia in Parkinson’s disease. A community- based, 4 
year longitudinal study. 
In order to identify whether cognitive impairment is associated with later development 
of dementia, the 76 non-demented PD patients were re-examined 4 years later. Twenty-five 
(42%) PD patients were demented at follow-up, whereas 35 PD remained without dementia. 
Compared to patients who did not become demented during the study period, those who 
became demented had lower baseline scores on the MMSE, Benton Visual Retention Test, 
and Judgement of Line Orientation; performed more slowly and had more errors on the 
Stroop Word Test third card; had more advanced PD, and had a trend toward higher 
depression score and older age. Factors significantly associated with incident dementia in the 
bivariate analysis were entered together with covariates (age, gender, education, age at disease 
onset, disease duration) in a logistic regression analysis to identify possible risk factors for 
dementia in PD. Time to complete the 3rd card of the Stroop Word Test was the only variable 
that was found to be independently associated with dementia.  
 
Report 3: Subtypes of mild cognitive impairment in Parkinson’s disease: progression to 
dementia. 
In order to identify potential subtypes of MCI in PD and establish whether MCI tends 
to progress to dementia, 72 of the non-demented PD patients were assessed at baseline and 4 
years later. Thirty-eight patients were diagnosed with MCI (amnestic n=6, single non-memory 
domain n=17, multiple domains slightly impaired n=15). At follow-up, 18 (62%) of the 
patients with MCI and 6 (20%) of the cognitively intact PD patients were demented. The 
difference was statistically significant (p=.001). Single domain non-memory MCI and 
multiple domain slightly impaired MCI were associated with subsequent development of 
dementia (p=0.003, p=0.04), while amnestic MCI was not (p=0.76). 
   
Report 4: Cognitive profiles of individual patients with Parkinson’ disease and dementia: a 
comparison with dementia with Lewy bodies and Alzheimer’s disease. 
 In order to describe the pattern of cognitive profiles within a community-based sample 
of PD patients with dementia we used cluster analysis on the raw subscores on the DRS. The 
results were compared with data from patients with DLB and AD. Fifty patients with PDD 
and 39 with AD from Stavanger, Norway, and 60 patients with DLB from San Diego, USA 
were included in the analysis. Four subgroups were identified: two subgroups with a 
subcortical cognitive profile (one with mild and one with moderate dementia severity), one 
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subgroup with global impairment and severe dementia, and one subgroup with a cortical 
cognitive profile and moderate dementia. Twenty-eight (56%) of the patients with PDD and 
34 (55%) of the patients with DLB were included in one of the two groups with a subcortical 
cognitive profile, compared to only 33% of the patients with AD (chi square=12.52, df=2, 
p=0.002). Conversely, 30% of the patients with PDD and 26% of those with DLB were 
included in the group with a cortical cognitive profile, compared to 67% of the patients with 
AD.  
 
 
DISCUSSION 
  
Heterogeneity of cognitive impairment in Parkinson’s disease 
 The results confirm that cognitive impairment is common in non-demented PD 
patients and that the cognitive impairment is heterogeneous in its presentation. Over 50% of 
the non-demented patients with PD had some form of cognitive impairment: 19% exhibited 
predominantly memory impairment and /or visuospatial impairment, 30% a dominant 
executive impairment, and 51% had a global cognitive impairment. 
 Similarly, cognitive heterogeneity was also present within the group of patients with 
PDD. The majority of PDD patients with mild to moderate dementia exhibited a subcortical 
cognitive profile, while a small proportion exhibited a cortical cognitive profile. The patients 
with DLB showed a similar pattern of cognitive impairment supporting and extending 
previous research showing both a clinical and neurobiological similarity between DLB and 
PDD (Ballard et al., 2002; Harding, Broe, & Halliday, 2002; Tiraboschi et al., 2000). These 
findings suggest that these syndromes represent aspects of a continuum of LB disease rather 
than distinct disease entities. Previous findings from MRI and neurochemical studies suggest 
that distinct brain changes are related to the different cognitive impairments in PD.  For 
example, memory impairment is related to hippocampal atrophy, whereas attention and 
executive impairment is related to atrophy of prefrontal cortex (Bruck, Kurki, Kaasinen, 
Vahlberg, & Rinne, 2004). Neurochemically, executive and attention deficits appear to be 
associated with dopaminergic disturbances within fronto-subcortical circuits (Owen, 2004), 
whereas cholinergic deficits, which  are also marked in patients with PD and dementia 
(Jellinger, 1999a), may be causally linked to the impairment of memory and attention seen in 
PD. The different cognitive profiles observed in this thesis strongly suggest marked inter-
 28
individual differences in the relative severity of the different brain changes, leading to 
different cognitive subtypes. However, clinico-pathologic studies are needed to explore how 
the different neuropsychological profiles specifically relate to distinct brain changes. Another 
unexplored issue is whether the cognitive subgroups are stable across the full spectrum of 
cognitive impairment in PD, i.e. whether the PD patients with MCI of the executive type will 
progress to a dysexecutive PDD syndrome, or whether the cognitive profile changes over time 
in the individual patient. The present findings underline that a considerable proportion of 
patients with PDD, as well as DLB, have a cortical cognitive profile which is similar to the 
profile in patients with AD. This finding has implications for the diagnostic clinical practice, 
although it is possible that somewhat different results might emerge with the use of a more 
extensive and detailed neuropsychological battery.  
 
 
Cognitive risk factors for dementia in Parkinson’s disease 
The results show that impaired performance on an executive test (Stroop Word Test), 
but not on tests sensitive to memory or visuospatial dysfunction, was the only independent 
risk factor associated with dementia. This finding is consistent with previous longitudinal 
studies reporting that impairments on selected neuropsychological tests, such as memory and 
executive functioning, are associated with later dementia (Levy, Jacobs et al., 2002; Mahieux 
et al., 1998). Impaired performance on a verbal fluency test (shopping list from DRS) was not 
associated with later development of dementia either, although previous studies (Jacobs et al., 
1995; Levy, Jacobs et al., 2002) reported the opposite. Discrepant findings regarding whether 
or not verbal fluency is an independent predictor of dementia in PD may be due to differences 
in task demands and instructions (Jacobs et al., 1995). Better preserved recognition memory 
in non-demented PD patients compared to recall memory might explain why impaired 
performance on Benton Visual Retention Test was not found to be an independent predictor 
of later dementia in our study.  
 The present findings indicate that executive dysfunction is the initial manifestation of 
dementia in PD, and that the changes may spread from fronto-striatal circuits to subsequently 
involve hippocampus and temporal-parietal cortex. 
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Mild cognitive impairment  and progression to dementia in Parkinson’s disease  
52.7% of the non-demented patients fulfilled our criteria for MCI. Three subtypes of 
MCI were identified based on explicit criteria: amnestic MCI (15.8%) single domain non-
memory MCI (44.7%) and multiple domains slightly impaired MCI (39.5%). The majority of 
the non-demented PD patients with MCI (62%) developed dementia during the four-year 
follow-up, compared to only a small proportion (20%) of the cognitively intact PD patients. 
This is a novel finding, to our knowledge not previously reported in the literature, showing a 
conversion rate of MCI to dementia as high as in individuals with MCI in the general 
population. These findings suggest that MCI is not a stable condition of PD, but rather 
represents the initial stage of a progressive cognitive decline leading to dementia. PD patients 
with non-memory MCI subtypes (i.e. single non-memory domain and multiple domains 
slightly impaired) were more likely to become demented than patients with amnestic MCI. 
However, the low number of patients limits the generalizability of the results. Longitudinal 
studies including a larger number of patients with PD-MCI are needed to evaluate whether the 
rate of progression to dementia differs for the different cognitive subtype of MCI in PD.  
 It should be pointed out that the findings that MCI in PD progresses to dementia must 
be interpreted with some caution. Although there is largely agreement about the existence of 
MCI in the general population and several subtypes MCI have been described (Petersen, 
2004), the concept of MCI having a role in PD patients is new and has not been  validated yet. 
However, although slightly modified, the MCI criteria used in the present thesis are in 
agreement with the current consensus view about MCI. Finally, the growing evidence of 
cognitive and neuropathological heterogeneity in PD patients (Foltynie et al., 2002; Lewis, 
Foltynie et al., 2005) supports the hypothesis that MCI is a useful prognostic sign for patients 
with PD.  
 
Cognitive functioning and motor symptoms 
 Patients with left-sided parkinsonism performed poorer than right-sided patients only 
on the Benton Visual Retention Test. Previous studies suggested that patients with onset of 
PD on the left side performed poorer than patients with right-sided onset on several cognitive 
measures (Tomer et al., 1993), although such a relationship has not been consistently 
observed (Finali et al., 1995; St Clair et al., 1998). Furthermore, no significant differences in 
neuropsychological test performance were seen between the akinetic versus tremor groups. 
These were surprising findings as previous research had shown better cognitive performance 
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in the tremor group, compared to the akinetic group (Ebmeier et al., 1990; Huber et al., 1988; 
Marttila & Rinne, 1976). Again, the low number of patients and the resulting low statistical 
power might have influenced the conclusion. 
 
Cognitive functioning and depression     
In the present thesis, depression did not differ between the cognitive intact and 
cognitive impaired PD patients, suggesting that the observed cognitive impairments in the 
current thesis can not be explained exclusively by the presence of depression. Furthermore, 
depression did not seem to be an independent risk factor for the development of dementia, as 
has been reported by other studies (Hobson & Meara, 2004; Hughes et al., 2000; Mahieux et 
al., 1998; Aarsland et al., 2001). Thus, our findings suggest that depression coexists with 
rather than contributes to the development of dementia, i.e. “the depression of dementia as 
opposed to the dementia of depression” (Andersen, Vestergaard, Riis, & Ingeman-Nielsen, 
1996).  
 
Medication effects on cognition in Parkinson’s disease 
 As previously described, medication with levodopa may affect cognitive functioning, 
but we did not find any association between the levodopa dose and the pattern of cognitive 
deficits. Furthermore, none of the patients included in the study were on anticholinergic 
drugs. Thus, a pharmacological explanation for our findings does not seem likely. Further 
studies including drug naïve patients will be needed to definitively resolve the impact of 
pharmacological drugs on cognitive functioning in PD, particularly from a longitudinal 
perspective. 
 
Clinical implications of the findings 
 Early identification of PD patients at high risk of developing dementia has important 
clinical consequences for the management of these patients. It is established that dementia in 
PD contributes to caregiver distress, placement in nursing homes, and reduced quality of life 
in these patients.  Cognitive assessment should therefore be regularly performed in patients 
with PD to carefully monitor their cognitive abilities. We have shown that even brief test 
batteries may identify patients at high risk for dementia.  
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In addition, the finding that different cognitive profiles exist in PDD (and DLB), 
strongly argues against that these disorders should be diagnosed only in the presence of an 
executive-visuospatial type of cognitive impairment. 
Finally, although, treatment is now available for PD with dementia, future studies are 
urgently needed to explore whether the progression from MCI to dementia in PD can be 
reduced or even prevented. With the high risk of progression to dementia, PD patients with 
MCI constitute a potential target group for testing new preventive treatment strategies such as 
proteasome inhibitors. The findings of distinct cognitive sub-groups with apparently different 
underlying brain substrates suggest the possibility that sub-groups of patients who may 
respond differently to different anti-dementia drugs will be identifiable by means of 
neuropsychological testing. 
 
 
Conclusions 
 
 Cognitive impairment is common in patients with PD. Different subtypes of MCI have 
been described, and MCI is a marker of subsequent development of dementia. MCI can be 
understood as the initial stage of a progressive cognitive decline leading to dementia in PD. 
The cognitive profiles obtained in both demented and non-demented patients with PD confirm 
the heterogeneity of cognitive impairment in PD. They also indicate that in most patients with 
PD, fronto-subcortical changes are the main contributing factor to dementia, whereas in other 
patients, cortical and hippocampal changes are more important. From a clinical standpoint, 
neuropsychological assessment is crucial for detecting mild cognitive impairment and early 
dementia in PD. It should hence be included in the routine evaluation of patients with PD in 
order to allow effective management of the patients. In addition, the neuropsychological 
assessment can provide the patients and their families with adequate information enabling 
them to conduct a proper planning of their own future needs.  
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